All Tissue/Cell Product Firms Must Register With CBER Under Proposed Rule
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of human cellular and tissue-based products will be required to register and list their products with the Center for Biologics Evaluation and Research regardless of whether their products fall under the agency's new tissue regulation or continue to be regulated as devices or biologics, FDA says in a May 14 proposed rule.